/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.31%
Natural Gas
+6.26%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.26%
VIX
N/A
Economic Calendar
EUR/USD
+0.31%
Natural Gas
+6.26%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.26%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
XRP Price Forecast: JPMorgan Cross-Border Payments Could Drive XRP to $1,000, Analyst says
28 minutes ago
Shiba Inu (SHIB) Overtakes BTC and DOGE as Most-Traded Coin in India
41 minutes ago
The Week Ahead: The RBA and the BoE in Focus Amidst Shifting Policy Outlooks
about 8 hours ago
Five Things to Know in Crypto This Week: US Jobs Report Offers Relief
1 day ago
Shiba Inu Price Surges as PayPal announces SHIB Token Integration in USA
1 day ago
ISM Services PMI Drops To 49.4, Missing Analyst Expectations
2 days ago
Silver Prices Forecast: Is Silver Set for Further Declines Amid Risk-On Trends?
about 1 hour ago
Week Ahead: BoE and UK GDP in the Spotlight
about 3 hours ago
Bitcoin (BTC) News Today: FOMC Member Speeches to Drive BTC Price Trends
about 6 hours ago
Gold Prices Forecast: Will Rising Risk Appetite Suppress Gold Further?
about 6 hours ago
XRP News Today: Uncertainty Looms Ahead of SEC’s Monday Filing
about 7 hours ago
USD/JPY Weekly Forecast: BoJ Eyes Services PMI, Wages, and Household Spending
about 9 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
PRTA
profile
Prothena Corporation plc
Follow
PRTA
(
Nasdaq - US
)
N/A
22.90
+0.86 (+3.90%)
in
:
usd
•
As of: May 03, 2024 15:59
UTC -4
Open
22.93
High
23.68
Low
22.75
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Prothena Corporation plc
CEO
Gene G. Kinney
Auditor
KPMG LLP
Sector
health technology
Employees
173
Headquarters
77 sir john rogerson's quay, block c, grand canal docklands
dublin, l2 d02 vk60, ireland
Website
www.prothena.com
Industry
biotechnology
Share Holders
5,221
Company Overview
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Prothena Corporation plc
Statistics
Valuation Measures
Market Capitalization
2
1.23B
Enterprise Value
610.01M
Enterprise Value/EBITDA
(ttm)
-3.34
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
2.11
Price to Sales
(ttm)
12.96
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
100.00%
Operating Margin
(ttm)
-160.91%
Profit Margin
(ttm)
-6211.51%
Return on Equity
(ttm)
-24.84%
Return on Invested Capital
(ttm)
-25.57%
Return on Assets
(ttm)
-20.24%
Income Statement
Revenue
(ttm)
91.37M
Revenue Per Share
(ttm)
1.70
Gross Profit
(ttm)
91.37M
EBITDA
(ttm)
3
-182.62M
Net Income Avi to Common
(ttm)
-147.03M
Diluted EPS
(ttm)
-2.80
Share Statistics
Beta (5Y Monthly)
0.30
52-Week Change
-70.86%
S&P500 52-Week Change
26.43%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
53.72M
Dividend Yield
0.00%
Float
4
38.57M
%
Held by Insiders
28.20%
%
Held by Institutions
97.08%
Balance Sheet
Total Cash
(mrq)
620.18M
Total Cash Per Share
(mrq)
11.54
Total Debt
(mrq)
0.00
Total Debt/Equity
(mrq)
0.00%
Current Ratio
(mrq)
11.24%
Quick Ratio
(mrq)
11.24%
Book Value Per Share
(mrq)
10.46
Cash Flow
Operating Cash Flow Per Share
(ytd)
-2.52
Free Cash Flow
(ytd)
-136.68M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker